Related Experiment Video
Updated: May 4, 2026

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance
Published on: February 17, 2023
Hypoadiponectinemia in obesity: association with insulin resistance
Jai Prakash1, Balraj Mittal2, Shally Awasthi3
1Department of Physiology, King George's Medical University, Lucknow, UP India.
Abstract:
Obesity is risk factor for insulin resistance, diabetes, and other chronic diseases. Adiponectin, an adipose-specific protein with antiatherogenic and antiinflammatory effects, were found to be associated with obesity, type 2 diabetes, and insulin resistance. Our aim to identify possible relationships between circulating adiponectin and obesity as well as obesity related phenotypes. A total of 642, obese and non-obese individuals were included in this cross-sectional study. Hormone and glucose levels were estimated using standard protocols. The adiponectin levels showed a significant decrease with increasing quartiles of insulin resistance index. Subjects in lowest quartile of adiponectin level had a significantly higher risk than those in the highest quartile, with higher body mass index, waist circumference, blood pressure, percentage body fat, fat mass, fasting insulin, insulin resistance index, total cholesterol (p < 0.001), low density lipoprotein-cholesterol (p = 0.001), very low density lipoprotein-cholesterol (p = 0.002), and Triglyceride (p = 0.002). The present study indicates that adiponectin is significantly associated with obesity, insulin resistance and other obesity related phenotypes.
More Related Videos
10:40Characterization of Adipocyte-Derived Extracellular Vesicle Secretion Using a CD63-GFP Reporter Mouse Model In Vivo and In Vitro
Published on: December 5, 2025
09:20An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function
Published on: May 4, 2021
Related Concept Videos
Obesity
Type II Diabetes II: Pathophysiology
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Insulin: The Receptor and Signaling Pathways
Type I Diabetes III: Clinical Manifestations
Drug Dosing: Obese Patients